BSEBeryl Drugs LtdLowNeutral
Announced Tue, 24 Mar · 16:40 IST

DISCLOSURE UNDER REGULATION 29(2) UNDER SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVER) REGULATIONS, 2011

Promoter Stake BuyCreeping Acquisition Near ThresholdOwnership Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-12.4%1-day move
₹21.00
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-12.4-8.2-9.6-10.2-10.2+19.0+17.6+4.8-9.5+11.9
Up moveDown movePending
AI summary

Mr. Sudhir Sethi, a main promoter of Beryl Drugs Ltd, acquired 7,500 equity shares of the company through market transactions on 23-03-2026, representing 0.14% of the total share capital. This takes his individual holding from 4,78,983 shares (9.44%) to 4,86,483 shares (9.58%). The total equity share capital of the company remains unchanged at 50,71,700 shares. The disclosure was filed under SEBI's Takeover Regulations and also lists other promoter-group members including Sanjay Sethi, Sangita Sethi, and Soniya Sethi.

Likely market impact

This is a small, routine promoter purchase and is not material in size — at 7,500 shares it is unlikely to move the stock price. However, the promoter is now sitting just below the 10% substantial-shareholder threshold, which is worth watching as further purchases could trigger additional disclosure obligations.